Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma
- First Online:
- Cite this article as:
- Song, Y., Cao, Z., Su, Q. et al. Chin. -Ger. J. Clin. Oncol. (2009) 8: 585. doi:10.1007/s10330-009-0153-0
We evaluated the value of using a panel of GC B-cell (CD10 and Bcl-6) and activation (MUM1, CD138 and Bcl-2) markers by immunohistochemistry to define prognosis in patients with diffuse large B-cell lymphoma (DLBCL).
Two different models (Hans’ and modified Chang’s model) were applied on 136 de novo DLBCL patients. Median follow-up in all patients was 39 months (range 5–80 months).
According to Hans’ model, patients with GCB had much better overall survival (5-year OS, 75%) than those with non-GCB (5-year OS, 52%) (Kaplan-Meier survival analysis, P < 0.05, log rank test). According to modified Chang’s model, patients with group 1 had much better overall survival (5-year OS, 78%) than those with group 3 (5-year OS, 44%) while group 2 had no significant value compared with group 1 and group 3 in prognosis (Kaplan-Meier survival analysis, P < 0.05, log-rank test). Using multivariate Cox proportional hazards regression analysis, the international prognostic index scores (IPI), expression of CD138 and the expression pattern of modified Chang’s model were independent prognostic indicators.
Our results suggest that the expression patterns of the panel of GCB-cell and activation markers by immunohistochemistry correlate with prognosis of patients with DLBCL and both models can be used well in ordinary work.